Scholarlink

Background <p>Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may lead to financial toxicity (FT), potentially impairing survivors’ quality of life (QoL). We assessed FT from the perspective of CRS/HIPEC candidates and survivors, hypothesizing an association with QoL, and explored its dynamics and drivers.</p> Patients and Methods <p>A cross-sectional, single-center study used in-person Comprehensive Score for Financial Toxicity (COST) (FT) and Functional Assessment of Cancer Therapy-General (FACT-G) (QoL) surveys among CRS/HIPEC candidates/survivors with various primary tumors up to 5 years postoperatively. Spearman correlation between COST and FACT-G was assessed. Risk factors for FT were identified using a generalized linear model with forward selection among clinical, sociodemographic, and financial variables, as well as time from CRS/HIPEC.</p> Results <p>Overall, 248 surveys were analyzed: 55 (22.2%) candidates and 193 (77.8%) survivors. Mean ± standard deviation (SD) age was 59 ± 11 years, and 75% were female individuals. Appendix cancer was the most prevalent (42.3%), followed by ovarian (33.9%), colon (14.5%), and other (9.3%). The mean ± SD COST score was 29.7 ± 10.7 (range: 0–44), with 31.0% experiencing moderate-to-severe FT (COST ≤ 25). COST and FACT-G scores were strongly correlated (rho = 0.51, p &lt; 0.001). Risk factors for greater FT (p &lt; 0.05) included preoperative (β = −3.7) and adjuvant chemotherapy (β = −3.2), identifying as Black, Indigenous, or person of color (β = −5.4), being single (β = −3.5), and higher co-pays within 90 days before/after CRS/HIPEC (β range: −3.0 to −3.9). FT decreased over time (<i>p</i> = 0.008), reaching its lowest levels by 1 year postoperatively.</p> Conclusions <p>FT is strongly associated with poorer QoL among CRS/HIPEC candidates/survivors. Risk factors include perioperative chemotherapy, higher co-pays from perioperative care, and sociodemographic disadvantages. Financial well-being improves by 1 year post-CRS/HIPEC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  • 期刊论文

  • 发表日期：

    2026年3月2日

查看全文
  • Vladislav Kovalik,
  • Armando Sardi,
  • Luis Felipe Falla-Zuniga,
  • Abeerah Wasti,
  • Mary Caitlin King,
  • Sergei Iugai,
  • Kseniia Uzhegova,
  • Carol Nieroda,
  • Teresa Diaz Montes,
  • Vadim Gushchin

摘要

Background

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may lead to financial toxicity (FT), potentially impairing survivors’ quality of life (QoL). We assessed FT from the perspective of CRS/HIPEC candidates and survivors, hypothesizing an association with QoL, and explored its dynamics and drivers.

Patients and Methods

A cross-sectional, single-center study used in-person Comprehensive Score for Financial Toxicity (COST) (FT) and Functional Assessment of Cancer Therapy-General (FACT-G) (QoL) surveys among CRS/HIPEC candidates/survivors with various primary tumors up to 5 years postoperatively. Spearman correlation between COST and FACT-G was assessed. Risk factors for FT were identified using a generalized linear model with forward selection among clinical, sociodemographic, and financial variables, as well as time from CRS/HIPEC.

Results

Overall, 248 surveys were analyzed: 55 (22.2%) candidates and 193 (77.8%) survivors. Mean ± standard deviation (SD) age was 59 ± 11 years, and 75% were female individuals. Appendix cancer was the most prevalent (42.3%), followed by ovarian (33.9%), colon (14.5%), and other (9.3%). The mean ± SD COST score was 29.7 ± 10.7 (range: 0–44), with 31.0% experiencing moderate-to-severe FT (COST ≤ 25). COST and FACT-G scores were strongly correlated (rho = 0.51, p < 0.001). Risk factors for greater FT (p < 0.05) included preoperative (β = −3.7) and adjuvant chemotherapy (β = −3.2), identifying as Black, Indigenous, or person of color (β = −5.4), being single (β = −3.5), and higher co-pays within 90 days before/after CRS/HIPEC (β range: −3.0 to −3.9). FT decreased over time (p = 0.008), reaching its lowest levels by 1 year postoperatively.

Conclusions

FT is strongly associated with poorer QoL among CRS/HIPEC candidates/survivors. Risk factors include perioperative chemotherapy, higher co-pays from perioperative care, and sociodemographic disadvantages. Financial well-being improves by 1 year post-CRS/HIPEC.